3CL2

N1 Neuraminidase N294S + Oseltamivir


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.54 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.240 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Collins, P.J.Haire, L.F.Lin, Y.P.Liu, J.Russell, R.J.Walker, P.A.Skehel, J.J.Martin, S.R.Hay, A.J.Gamblin, S.J.

(2008) Nature 453: 1258-1261

  • DOI: 10.1038/nature06956
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by ...

    The potential impact of pandemic influenza makes effective measures to limit the spread and morbidity of virus infection a public health priority. Antiviral drugs are seen as essential requirements for control of initial influenza outbreaks caused by a new virus, and in pre-pandemic plans there is a heavy reliance on drug stockpiles. The principal target for these drugs is a virus surface glycoprotein, neuraminidase, which facilitates the release of nascent virus and thus the spread of infection. Oseltamivir (Tamiflu) and zanamivir (Relenza) are two currently used neuraminidase inhibitors that were developed using knowledge of the enzyme structure. It has been proposed that the closer such inhibitors resemble the natural substrate, the less likely they are to select drug-resistant mutant viruses that retain viability. However, there have been reports of drug-resistant mutant selection in vitro and from infected humans. We report here the enzymatic properties and crystal structures of neuraminidase mutants from H5N1-infected patients that explain the molecular basis of resistance. Our results show that these mutants are resistant to oseltamivir but still strongly inhibited by zanamivir owing to an altered hydrophobic pocket in the active site of the enzyme required for oseltamivir binding. Together with recent reports of the viability and pathogenesis of H5N1 (ref. 7) and H1N1 (ref. 8) viruses with neuraminidases carrying these mutations, our results indicate that it would be prudent for pandemic stockpiles of oseltamivir to be augmented by additional antiviral drugs, including zanamivir.


    Organizational Affiliation

    MRC-National Institute for Medical Research, Mill Hill, London NW7 1AA, UK.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Neuraminidase
A, B, C, D, E, F, G, H
385Influenza A virus (A/Viet Nam/1203/2004(H5N1))Mutation(s): 1 
Gene Names: NA
EC: 3.2.1.18
Find proteins for Q6DPL2 (Influenza A virus)
Go to UniProtKB:  Q6DPL2
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G39
Query on G39

Download CCD File 
A, B, C, D, E, F, G, H
(3R,4R,5S)-4-(acetylamino)-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid
C14 H24 N2 O4
NENPYTRHICXVCS-YNEHKIRRSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
G39IC50:  3.700000047683716   nM  BindingDB
G39Ki:  4.900000095367432   nM  BindingDB
G39Ki :  25.899999618530273   nM  PDBBind
G39Ki:  1.100000023841858   nM  BindingDB
G39IC50:  11   nM  BindingDB
G39IC50:  0.20000000298023224   nM  BindingDB
G39IC50:  0.8999999761581421   nM  BindingDB
G39IC50:  49   nM  BindingDB
G39IC50:  7.099999904632568   nM  BindingDB
G39IC50:  26   nM  BindingDB
G39IC50:  1.7999999523162842   nM  BindingDB
G39IC50:  2.200000047683716   nM  BindingDB
G39IC50:  2.5999999046325684   nM  BindingDB
G39IC50:  0.7300000190734863   nM  BindingDB
G39IC50:  0.6000000238418579   nM  BindingDB
G39IC50:  1.2999999523162842   nM  BindingDB
G39IC50:  0.30000001192092896   nM  BindingDB
G39IC50:  1   nM  BindingDB
G39Ki:  7.900000095367432   nM  BindingDB
G39IC50:  4.900000095367432   nM  BindingDB
G39Ki:  0.10000000149011612   nM  BindingDB
G39IC50:  0.10000000149011612   nM  BindingDB
G39IC50:  0.4000000059604645   nM  BindingDB
G39IC50:  1   nM  BindingDB
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.54 Å
  • R-Value Free: 0.263 
  • R-Value Work: 0.239 
  • R-Value Observed: 0.240 
  • Space Group: P 6
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 290.649α = 90
b = 290.649β = 90
c = 133.293γ = 120
Software Package:
Software NamePurpose
CrystalCleardata collection
AMoREphasing
PHENIXrefinement
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2008-05-20
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Non-polymer description, Version format compliance
  • Version 1.2: 2018-08-22
    Changes: Data collection, Database references, Source and taxonomy, Structure summary